Focused on Partnerships
We are applying our drug developing expertise to design novel anti-cancer medicines that address serious unmet medical needs in oncology and autoimmune disease. Our team of experts is capable of creating mAbs, multi-specific antibodies and ADCs against targets of interest and providing phase I-ready assets to partners.
Our three unique assets targeting oxMIF, the key to drugging MIF:
- ON203: OncoOne’s optimized mAb targeting oxMIF in solid tumors
- ON104: OncoOne’s oxMIF mAb specifically formulated for autoimmune disorders and severe inflammatory conditions
- ON-05: the first asset from OncoOne’s proprietary PreTarg-it™ platform combining the tumor aggregation of oxMIF and radiotherapy in a powerful, yet highly targeted radioimmunoconjugate therapy
We value our cooperation with excellent public grantpartners
and are proud to partner with top-tier academic collaborators.
Public Grants.
Austria Wirtschaftsservice GmbH
Austrian Federal Development and Financing Bank
Bundesministerium für Digitalisierung und Wirtschaftsstandort
Federal Ministry of Austria Digital and Economic Affairs
Bundesministerium für Verkehr, Innovation und Technologie
Federal Ministry of Austria Transport, Innovation and Technology
Österreichische Forschungsförderungsgesellschaft mbH
The Austrian Research Promotion Agency
Österreichische Forschungsförderungsgesellschaft mbH
The Austrian Research Promotion Agency
Collaborators.
GenScript PROBIO
Imperial College London
Massachusetts General Hospital / Harvard
University of Catania
Medizinische Universität Graz
Head offices
in Boston (USA) and Vienna (Austria)
Cooperation partners
from China, France, Germany, India, Italy, Netherlands, Northern Ireland, Switzerland, UK, US